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Abstract: Background Type 2 immunity serves to resist parasitic helminths, venoms, and toxins, but the
role and regulation of neutrophils during type 2 immune responses are controversial. Helminth models
suggested a contribution of neutrophils to type 2 immunity, whereas neutrophils are associated with
increased disease severity during type 2 inflammatory disorders, such as asthma. Objective We sought
to evaluate the effect of the prototypic type 2 cytokines IL-4 and IL-13 on human neutrophils. Methods
Human neutrophils from peripheral blood were assessed without or with IL-4 or IL-13 for (1) expression of
IL-4 receptor subunits, (2) neutrophil extracellular trap (NET) formation, (3) migration toward CXCL8
in vitro and in humanized mice, and (4) CXCR1, CXCR2, and CXCR4 expression, as well as (5) in
nonallergic versus allergic subjects. Results Human neutrophils expressed both types of IL-4 receptors,
and their stimulation through IL-4 or IL-13 diminished their ability to form NETs and migrate toward
CXCL8 in vitro. Likewise, in vivo chemotaxis in NOD-scid-Il2rg−/− mice was reduced in IL-4–stimulated
human neutrophils compared with control values. These effects were accompanied by downregulation of
the CXCL8-binding chemokine receptors CXCR1 and CXCR2 on human neutrophils on IL-4 or IL-13
stimulation in vitro. Ex vivo analysis of neutrophils from allergic patients or exposure of neutrophils
from nonallergic subjects to allergic donor serum in vitro impaired their NET formation and migration
toward CXCL8, thereby mirroring IL-4/IL-13–stimulated neutrophils. Conclusion IL-4 receptor signaling
in human neutrophils affects several neutrophil effector functions, which bears important implications for
immunity in type 2 inflammatory disorders.
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Background:  Type 2 immunity serves to resist parasitic helminths, venoms and 20 
toxins, but the role and regulation of neutrophils during type 2 immune responses is 21 
controversial. Helminth models suggested a contribution of neutrophils to type 2 22 
immunity, whereas neutrophils are associated with increased disease severity during 23 
type 2 inflammatory disorders such as asthma.  24 
Objective:  To evaluate the impact of the prototypic type 2 cytokines interleukin-4 25 
(IL-4) and IL-13 on human neutrophils.  26 
Methods:  Human neutrophils from peripheral blood were assessed without or with 27 
IL-4 or IL-13 for (i) expression of IL-4 receptor (IL-4R) subunits; (ii) neutrophil 28 
extracellular trap (NET) formation; (iii) migration toward CXC chemokine ligand 8 29 
(CXCL8) in vitro and in humanized mice; (iv) CXC chemokine receptor 1 (CXCR1), 30 
CXCR2, and CXCR4 expression; and (v) in non-allergic versus allergic subjects. 31 
Results:  Human neutrophils expressed both types of IL-4Rs and their stimulation via 32 
IL-4 or IL-13 diminished their ability to form NETs and migrate toward CXCL8 in 33 
vitro. Likewise, in vivo chemotaxis in NOD-scid-Il2rg–/– mice was reduced in IL-4-34 
stimulated human neutrophils compared to controls. These effects were accompanied 35 
by downregulation of CXCL8-binding chemokine receptors CXCR1 and CXCR2 on 36 
human neutrophils upon IL-4 or IL-13 stimulation in vitro. Ex vivo analysis of 37 
neutrophils from allergic patients or exposure of neutrophils from non-allergic 38 
individuals to allergic donors' serum in vitro impaired their NET formation and 39 
migration toward CXCL8, thereby mirroring IL-4/IL-13-stimulated neutrophils.  40 
Conclusion:  Signaling in human neutrophils affects several neutrophil effector 41 




Key messages:  45 
• IL-4R stimulation on human neutrophils by IL-4 or IL-13 decreased NET 46 
formation. 47 
• Stimulation of IL-4R on human neutrophils downregulated their CXCR1 and 48 
CXCR2 and impaired their chemotaxis to CXCL8 in vitro as well as in NOD-scid-49 
Il2rg–/– mice. 50 
• In vivo or in vitro exposure of neutrophils to allergic patients' serum decreased 51 
CXCR1 and CXCR2 as well as impaired NET formation and migration, thereby 52 
mirroring IL-4/IL-13-stimulated neutrophils. 53 
 54 
Capsule summary: IL-4 receptor engagement in human neutrophils impairs their 55 
formation of extracellular traps and their in vitro and in vivo chemotaxis. 56 
 57 
Key words: allergy; neutrophil; innate immunity; IL-4; IL-13; IL-4 receptor; 58 
inflammation. 59 
 60 




Neutrophil granulocytes (neutrophils) are the first non-resident immune cells to react 64 
to pathogen- or danger-associated stimuli and they rapidly migrate to the site of 65 
inflammation. Migration of neutrophils is governed by the expression of the 66 
chemokine receptors CXC chemokine receptor 1 (CXCR1) and CXCR2 versus 67 
CXCR4. Thus, downregulation of CXCR4 and upregulation of CXCR2 on 68 
neutrophils maturing in the bone marrow allows these cells to leave the organ and join 69 
the migratory pool of blood neutrophils.1-3 On the contrary, senescent or non-70 
migratory neutrophils upregulate CXCR4. In the target tissue, neutrophils employ 71 
different effector functions, including phagocytosis and the secretion of cytotoxic 72 
granules and cytokines. Moreover, activated neutrophils can initiate a cellular 73 
program leading to the release of neutrophil extracellular traps (NET) to immobilize 74 
and kill large microbes.4,5 NETs are web-like structures composed of decondensed 75 
mitochondrial or nuclear DNA that are associated with modified histone proteins and 76 
different antimicrobial peptides, such as neutrophil elastase and myeloperoxidase 77 
(MPO). Neutrophils release NETs in response to a range of stimuli, including phorbol 78 
12-myristate 13-acetate (PMA), CXCL8 (also termed interleukin-8 [IL-8]), crystals, 79 
lipopolysaccharide (LPS), and microorganisms. NETs not only contribute to pathogen 80 
defense, but they are also associated with non-infectious disorders, including 81 
vasculitis and systemic lupus erythematosus. 82 
 Neutrophils are predominant in type 1 (or T helper [Th] 1 cell) and type 3 83 
(Th17 cell) immune responses. However, the regulation and role of neutrophils during 84 
type 2 (or Th2 cell) immune responses remains ill-defined.6-9 Type 2 immune 85 
responses evolved to protect the host against large extracellular parasitic helminths, 86 
venoms, and toxins by strengthening epithelial barrier defenses and stimulating 87 
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different immune cell mechanisms.10,11 Many of these effects are initiated, driven and 88 
maintained by the actions of type 2 cytokines, most notably IL-4 and IL-13, which 89 
signal via heterodimeric IL-4 receptors (IL-4R). IL-4 binds and signals via two 90 
different IL-4Rs, termed type 1 and type 2 IL-4R, respectively (Fig. 1A). The type 1 91 
IL-4R consists of a heterodimer made of IL-4Ra (also termed CD124) and the 92 
common gamma chain (also known as gc or CD132). The type 2 IL-4R is composed 93 
of CD124 and IL-13Ra1 (also named CD213a1). IL-13Ra2 (also termed CD213a2) 94 
serves as a decoy receptor for IL-13. In addition to IL-4, IL-13 also associates with 95 
and signals through the type 2 IL-4R. IL-4 and IL-13 mediate signaling via 96 
phosphorylation of Signal Transducer and Activator of Transcription 6 (STAT6),11,12 97 
but typically not of STAT5 and STAT3, whereas STAT5 and STAT3 become 98 
activated with gc cytokines and granulocyte colony-stimulating factor (G-CSF).13 99 
 In type 2 immunity, during certain helminth infections in mice, the recruitment 100 
of neutrophils contributed to early containment of the parasite during its migration 101 
through the lungs.14 Yet, in the same model, neutrophils also caused increased 102 
damage to the lungs.14,15 Considering type 2 inflammation in humans, as typically 103 
seen with atopic dermatitis and allergic asthma, some studies have shown that 104 
neutrophil responses were attenuated or maybe even suppressed, which has been 105 
attributed to reciprocal regulation of type 2 and type 3 inflammatory pathways.16,17 106 
However, neutrophils are present in certain severe forms of allergic asthma, which 107 
may result in a mixed type 2 and type 3 inflammation,6,18-21 and NETs have recently 108 
been associated with asthma exacerbations during rhinovirus infection of asthmatics.22 109 
Notably, coding polymorphisms in the human IL4Ra gene have been linked to 110 
susceptibility and severity of atopy and asthma in patients,23-25 as well as a mixed 111 
neutrophilic-eosinophilic type of severe experimental asthma in mice.26 Moreover, 112 
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recently, mice with a deficiency in IL-4, IL-13 or STAT6 were shown to exhibit a 113 
neutrophilic form of experimental asthma upon challenge.27 114 
 These data suggest that the IL-4R–STAT6 signaling pathway regulates 115 
neutrophils in type 2 inflammation, possibly via other, more rapid mechanisms than 116 
its involvement in type 2 vs. type 3 immune skewing. With the hypothesis that IL-4 117 
could directly affect neutrophils, as recently shown in mice,28 we have investigated in 118 
the present study expression and impact on primary human neutrophils of IL-4R 119 




Materials and Methods 123 
Human subjects 124 
Following written informed consent, volunteers were recruited for donating blood, 125 
which was immediately processed to isolate neutrophils. Serum was also obtained 126 
from the same donors for IgE detection using ImmunoCAP250 (Phadia, 127 
ThermoFisher). All experiments using human samples were carried out in accordance 128 
with the Cantonal Ethical Committee of Zurich (BASEC number 2016-01440). 129 
Healthy donors (HD) were defined as subjects with serum IgE levels below 100 kU/L 130 
and no history of seasonal or perennial allergies. Allergic donors (AD) were subjects 131 
with total serum IgE levels above 100 kU/L (mean 279.7 ± 184.9 kU/L) with a known 132 
allergy to grass pollen, tree pollen, or house dust mite, verified by a positive skin 133 
prick test or allergen-specific IgE test, and with specific clinical symptoms such as 134 
seasonal or perennial rhino-conjunctivitis and asthma. AD were investigated during 135 
their allergen season. Absolute neutrophil counts and percentages in peripheral blood 136 
were determined by an automated system (Abbott Diagnostics, Santa Clara). 137 
 138 
Isolation and in vitro stimulation of neutrophils 139 
Venous blood samples were collected in ethylenediaminetetraacetic acid (EDTA) 140 
tubes (BD Vacutainer®). Neutrophils were purified by HetaSepTM (Stemcell 141 
Technologies) followed by negative magnetic selection using the EasySep Direct 142 
Human Neutrophil Isolation Kit (Stemcell Technologies). Cell viability (>97%) was 143 
assessed by trypan blue exclusion and purity of neutrophil preparations (96.4 ±2.4%) 144 
was determined by flow cytometry based on CD16 (3G8, BioLegend), CD61 (VI-145 
PL2, BioLegend) and CD66b (G10F5, BioLegend). Purified neutrophils were 146 
resuspended in RPMI 1640 supplemented with 1% fetal bovine serum (FBS; 147 
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ThermoFisher), before stimulation with recombinant human cytokines (used 148 
throughout the study), including G-CSF, IL-4, and IL-13 (at 150 ng/mL, unless stated 149 
otherwise; PeproTech), for 0, 4, 6, and 24 h, or with serum from either HD or AD, 150 
followed by flow cytometry analysis (see below). Viability was measured using the 151 
Annexin V Apoptosis Detection kit (BD Biosciences) in combination with propidium 152 
iodide (PI). 153 
 154 
Flow cytometry 155 
Single-cell suspensions of neutrophils were processed for analysis by flow cytometry 156 
and stained using phosphate-buffered saline (PBS) with 1% FBS, 2 mM EDTA, and 157 
fluorochrome-conjugated monoclonal antibodies against the following human 158 
antigens (from BioLegend unless otherwise stated): CD16 (3G8), CD61 (VI-PL2), 159 
CD66b (G10F5), CD114 (LMM741), CD124 (G077F6), CD132 (TUGh4), CD162 160 
(KPL-1), CD213a1 (SS12B), CD213a2 (SHM38), CXCR1 (8F1/CXCR1), CXCR2 161 
(5E8/CXCR2), and CXCR4 (12G5). For MPO staining, neutrophils were fixed by 162 
addition of Fixation Buffer I, followed by permeabilization with Perm Wash Buffer 163 
III (BD Phosflow, BD Bioscience). Intracellular staining for MPO (MPO421-8B2) 164 
was performed according to manufacturer's instructions. Samples were acquired using 165 
a BD LSR Fortessa and analyzed using FlowJo software (Tristar). 166 
 167 
Assessment of intracellular signaling pathways 168 
Highly-purified neutrophils were stimulated in vitro in RPMI medium (RPMI 1640 169 
with 1% of FBS) and G-CSF, IL-4, or IL-13 (50 ng/mL) for 0, 2, 5, 15, 30, and 60 170 
min, followed by fixation with Fix Buffer I and permeabilization with Perm Buffer 171 
III. Intracellular staining for phospho-Y705 of STAT3 (pSTAT3; 13A3-1, 172 
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BioLegend), phospho-Y694 of STAT5 (pSTAT5; SRBCZX, ThermoFisher), 173 
phospho-Y641 of STAT6 (pSTAT6; CHI2S4, ThermoFisher) was performed as 174 
previously established.28,29 Samples were acquired and analyzed by flow cytometry, 175 
as stated above. 176 
 177 
SDS-PAGE and Western blot analysis 178 
107 neutrophils in RPMI 1640 supplemented with 1% FBS were stimulated with G-179 
CSF, IL-4, or IL-13 (50 ng/mL) for 0 and 5 min at 37°C. Subsequently, cells were 180 
lyzed with 4x Laemmli's buffer (Bio-Rad). Proteins were separated using 4–20% 181 
SDS-PAGE mini ready gels (Bio-Rad) and transferred to polyvinylidene difluoride 182 
(PVDF) membranes (Bio-Rad). Membranes were labeled with rabbit antibody (Cell 183 
Signaling Technology) for pSTAT3 (D3A7), pSTAT5, pSTAT6, total STAT3 184 
(79D7), total STAT5 (D206Y), total STAT6 (D3H4), and vinculin. After incubation 185 
with the appropriate primary antibody, the blots were developed with horseradish 186 
peroxidase-conjugated secondary antibodies by using enhanced chemiluminescence 187 
reagents (ThermoScientific) following standard protocols. 188 
 189 
Analysis of NETs 190 
105 neutrophils were seeded on glass coverslips treated with poly-lysine (Sigma) in 191 
24-well tissue culture plates and incubated for 6 h at 37°C in 5% CO2 with medium 192 
(RPMI 1640 with 1% of FBS) alone or with G-CSF, IL-4, or IL-13 (150 ng/mL). 193 
Subsequently, neutrophils were stimulated with 100 nM PMA (Sigma) for 2 h to 194 
induce NET formation. Cells were then fixed with 4% paraformaldehyde for 10 min 195 
at room temperature and mounted using ProLong Gold AntiFade with 4',6-diamidino-196 
2-phenylindole dihydrochloride (DAPI; Life Technologies). Cells were imaged using 197 
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a 40-fold magnification 1.25 NA with an inverted CSLM Leica SP5 confocal 198 
microscope (Leica). Every picture consisted of an overlay of 15 stacks of 20 µm. 199 
Quantification of NET+ neutrophils were done both manually and automatically using 200 
ImageJ software. For manual counting, 5 randomly selected areas of the same slide 201 
were counted by three independent investigators with two of them blinded to the 202 
treatment conditions. For automatic analysis, we used ImageJ software with the 203 
DANA plug-in to quantify the area, raw integrated density, aspect ratio, roundness, 204 
maximum and minimum brightness, and solidity of each region of interest of DAPI-205 
labeled neutrophils, as previously described.30 206 
 207 
Transwell migration assay 208 
Transwell migration assays were performed as previously published.28,31 In brief, 209 
freshly-isolated neutrophils were incubated for 2 h at 37°C in 5% CO2 with medium 210 
(RPMI 1640 containing 1% of FBS) alone or supplemented with 150 ng/mL G-CSF, 211 
IL-4, IL-13, or serum from HD or AD. Where indicated, neutrophils were incubated 212 
with cytokines, or with serum, or preincubated with rabbit anti-human IL-4Ra 213 
monoclonal antibody (anti-CD124; Sino Biological) for 1 h before seeding into the 214 
upper chamber of a 3 µm transwell (Corning Costar). Neutrophil migration toward 215 
CXCL8 (PeproTech), added to the lower chamber, was determined after 120 min by 216 
determining neutrophil counts in the lower chamber using flow cytometry counting 217 
beads (123count eBeads, ThermoFisher), as previously published.32,33 218 
 219 
Airpouch mouse model 220 
An airpouch was formed in the back of 2–4-month-old NOD-scid-Il2rg–/– (NSG; 221 
Charles River Laboratories) mice by subcutaneous injection of 3 mL filtered sterile air 222 
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on days 0 and 3, as described.28 On day 5, LPS (100 nM) and CXCL8 (100 ng/mL) in 223 
2 mL of PBS was injected into the airpouch along with intravenous injection of 107 224 
highly-purified human neutrophils pre-incubated for 2–6 h with medium (RPMI 1640 225 
medium with 1% FBS) alone or in combination with IL-4 (150 ng/mL), or G-CSF 226 
(150 ng/mL). Mice were euthanized after 90 min to collect airpouch infiltrate and 227 
spleens. Samples were analyzed by flow cytometry as stated above. Mouse 228 
experiments followed the Swiss Federal Veterinary Office guidelines and were 229 
approved by the Cantonal Veterinary Office. 230 
 231 
Statistics 232 
The numbers of samples and subjects used in each experiment are indicated in the 233 
figure legends. Data are presented as mean ± standard deviations (SD). P-values were 234 
calculated using Student's t-test, two-way analysis of variance (ANOVA) with 235 
Bonferroni multiple comparison test, one-way ANOVA with Tukey’s multiple 236 
comparisons test, or Friedman test with Dunn’s multiple comparisons test as 237 
indicated. Statistical analysis was performed with Graph-Pad Prism. Statistical 238 




Human neutrophils express functional type 1 and type 2 IL-4Rs 242 
Previous studies found human neutrophils expressed both CD124 and CD132, thus 243 
forming type 1 IL-4Rs, whereas CD213a1 and CD213a2 were absent on these 244 
cells.34,35 We re-evaluated IL-4R expression on freshly-isolated human neutrophils. 245 
Notably, our neutrophil purification method, yielding on average 96.4% pure human 246 
neutrophils, did not significantly affect expression levels of CD16, CD66b, IL-4R 247 
subunits, crucial chemokine receptors, as well as CD49d, in comparison to the 248 
assessment of these molecules on neutrophils in whole blood (Fig. E1, A to C). We 249 
were able to detect CD124, CD132, and CD213a1 on purified human neutrophils 250 
right after isolation from whole blood of HD, and expression of these IL-4R subunits 251 
further significantly increased upon stimulation of neutrophils for 24 h with G-CSF (P 252 
< .0001, CD124 for G-CSF vs time 0; P < .0001, CD132 for G-CSF vs time 0; P = 253 
.0008, CD213a1 for G-CSF vs time 0; Fig. 1, B to D). Also, the decoy receptor 254 
CD213a2 was detectable on neutrophils and increased upon incubation of neutrophils 255 
with G-CSF (P = .0385, G-CSF vs time 0; Fig. E1B and E2). A resting period of 30 256 
to 120 min in medium or autologous serum following isolation did not change IL-4R 257 
expression (data not shown). 258 
 To investigate whether neutrophils expressed functional IL-4Rs resulting in 259 
phosphorylated STAT6 (pSTAT6), we performed time-course experiments in purified 260 
human neutrophils upon stimulation with IL-4 or IL-13, and G-CSF as a control. G-261 
CSF resulted in strong and significant activation of STAT3 (P < .0001) and STAT5 262 
(P = .0031) in human neutrophils 5 min after stimulation, whereas such treatment did 263 
not affect pSTAT6 levels (Fig. 1E). On the other hand, IL-4 and IL-13 significantly 264 
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activated STAT6 in human neutrophils, inducing a sharp peak in pSTAT6 5 min after 265 
cytokine stimulation (P < .0001, for both IL-4 and IL-13 at 5 min vs time 0), which 266 
declined thereafter (Fig. 1E). However, pSTAT3 and pSTAT5 expression did not 267 
change significantly following IL-4 or IL-13 stimulation (Fig. 1E). These findings 268 
were further confirmed by Western blot analysis (Fig. E3). 269 
 Together, these results demonstrate the presence of functional type 1 and type 270 
2 IL-4Rs on human neutrophils. 271 
 272 
IL-4R engagement impairs formation of NETs in human neutrophils 273 
To evaluate the effects of IL-4 and IL-13 on neutrophil effector functions we assessed 274 
NET formation upon stimulation with PMA (Fig. 2). Compared to medium or G-CSF, 275 
IL-4- or IL-13-conditioned neutrophils produced significantly less NETs, as assessed 276 
by manual counting (P < .0001, Medium vs IL-4;  P = .0001, Medium vs IL-13; P < 277 
.0001, G-CSF vs IL-4 or IL-13) and by automatic analysis of DNA area (P < .0001, 278 
Medium vs IL-4 or IL-13; P < .0001, G-CSF vs IL-4; P = .0037, G-CSF vs IL-13; 279 
Fig. 2, A and B). Moreover, the NETs of IL-4-/IL-13-stimulated neutrophils were of 280 
different characteristics featuring enlarged and less dense nuclei next to groups of 281 
round and condensed nuclei (Fig. 2A). These phenotypic differences were also 282 
responsible for the slight but non-significant difference in manual counting vs 283 
automatic analysis of NETs in medium-conditioned neutrophils (Fig. 2B). These data 284 




IL-4 and IL-13 inhibit chemotaxis of human neutrophils to CXCL8 in vitro 288 
To gain further insight into the effects of IL-4R stimulation on human neutrophils, we 289 
assessed in vitro migration of neutrophils using a transwell migration assay. When 290 
freshly-isolated human neutrophils were pre-incubated for different times without 291 
(Medium) or with IL-4 (Fig. 3, A and B) or IL-13 (Fig. 3, C and D), IL-4-/IL-13-292 
stimulated neutrophils showed decreased migration toward CXCL8 (which binds 293 
CXCR1 and CXCR2)3, with significant and consistent reduction in chemotaxis at 60 294 
(P = .0014 [in cell counts] and P = .0043 [in %] for IL-4 vs Medium; P < .0001 and P 295 
= .0042, for IL-13 vs Medium) and 120 min (P = .0029 and P = .0004 for IL-4 vs 296 
Medium; P < .0001 and P < .0001 for IL-13 vs Medium; Fig. 3, A to D). Next, we 297 
assessed the migration of human neutrophils toward different concentrations of 298 
CXCL8 pre-incubating the human neutrophils with IL-4 (Fig. 3E) or IL-13 (Fig. 3F). 299 
While 10 to 100 ng/mL CXCL8 exerted potent chemotactic activity on control 300 
neutrophils (medium), pre-incubation with IL-4 or IL-13 significantly decreased 301 
neutrophil chemotaxis at all CXCL8 concentrations of 1 ng/mL and higher (P = 302 
.0360, IL-4 vs Medium for 1 ng/mL; P = .0263, IL-4 vs Medium for 10 ng/mL; P = 303 
.0076, IL-4 vs Medium for 100 ng/mL; P = .0198, IL-13 vs Medium for 1 ng/mL; P = 304 
.0377, IL-13 vs Medium for 10 ng/mL; P = .0240, IL-13 vs Medium for 100 ng/mL; 305 
P = .0204, IL-13 vs Medium for 1000 ng/mL; Fig. 3, E and F). Finally, human 306 
neutrophils were incubated with different concentrations of either IL-4 or IL-13 307 
followed by chemotaxis toward a set concentration of CXCL8 (P = .0004, 150 ng/mL 308 
of IL-4 vs Medium; P = .0002, 150 ng/mL of IL-13 vs Medium). Both IL-4 and IL-13 309 
significantly inhibited neutrophil migration in a dose-dependent manner (Fig. 3, G 310 
and H). 311 
 312 
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IL-4R signaling hampers migration of human neutrophils in humanized mice 313 
To investigate whether IL-4R signaling inhibited the migration of human neutrophils 314 
in vivo, we challenged NSG mice harboring human neutrophils. To this end, we 315 
induced a sterile inflammation in form of an airpouch on the back of NSG mice by 316 
repeated injection of sterile air on days 0 and 3, followed by administration of the 317 
neutrophil chemoattractants CXCL8 and LPS into the airpouch and adoptive transfer 318 
of pre-conditioned human neutrophils via tail vein injection on day 5 (Fig. 4A). Mice 319 
were sacrificed 90 min after adoptive transfer of neutrophils to avoid loss of 320 
neutrophils, and we analyzed the airpouch infiltrate by flow cytometry by gating on 321 
human CD45-positive (and mouse CD45-negative) CD16+ CD66b+ cells (Fig. 4B). In 322 
the airpouch, the counts of human neutrophils were 4.2 times higher in the control 323 
group (Medium) compared to IL-4 (P = .0247; Fig. 4C). Conversely, the counts of 324 
infiltrating human neutrophils in spleen was comparable in both groups of mice (Fig. 325 
4C). Moreover, we compared G-CSF to IL-4, which confirmed that IL-4 pre-326 
conditioning significantly affected migration of human neutrophils into to the 327 
airpouch (P = .0214), but not the spleen (Fig. 4D). 328 
 329 
IL-4R engagement modulates chemokine receptors on human neutrophils 330 
The aforementioned data demonstrate that IL-4R engagement hampers the migration 331 
of human neutrophils in vitro and in vivo. These actions could, at least in part, result 332 
from changes in expression of CXCR1, CXCR2 and CXCR4. We assessed expression 333 
of these chemokine receptors in human neutrophils upon in vitro stimulation with IL-334 
4 or IL-13. As previously mentioned, the isolation method did not affect the 335 
expression of these chemokine receptors (Fig. E1C). Upon stimulation with either IL-336 
4 or IL-13, human neutrophils significantly downregulated CXCR1 (P = .0077, IL-4 337 
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vs Medium; P = .0031, IL-13 vs Medium) and CXCR2 (P = .0238, IL-4 vs Medium; 338 
P = .0170, IL-13 vs Medium) compared to incubation in medium (Fig. 5A). In 339 
contrast, CXCR4 expression did not significantly change in IL-4-/IL-13-conditioned 340 
neutrophils (Fig. 5A). The changes in CXCR1 and CXCR2 were not due to apoptosis, 341 
as shown by annexin V and PI staining, which remained below 5% during the 342 
incubation period (Fig. 5B). Collectively, IL-4-/IL-13-stimulated neutrophils adopt a 343 
chemokine receptor pattern akin to bone marrow-sessile, non-migratory cells. 344 
 345 
Neutrophils of allergic individuals resemble IL-4-/IL-13-stimulated cells 346 
The effects of IL-4R signaling on human neutrophils suggest that, in type 2 347 
inflammatory disorders, neutrophil functions could be affected. To investigate this 348 
hypothesis, we compared freshly-isolated neutrophils from healthy donors (HD) to 349 
patients with known active allergies (see Materials and Methods). Counts and 350 
percentages of neutrophils in peripheral blood of allergic donors (AD) were 351 
comparable to that of HD (Fig. 6A). However, neutrophils from AD exhibited 352 
differences in several functional markers, including a significant decrease in CD16 (P 353 
= .0071, AD vs HD; Fig. 6B). Moreover, neutrophils from AD showed significantly 354 
lower expression of CXCR1 (P = .0012, AD vs HD) and CXCR2 (P < .0001, AD vs 355 
HD), as well as a tendency toward higher CXCR4 levels (Fig. 6C). Thus, neutrophils 356 
of AD were reminiscent of IL-4-/IL-13-conditioned cells. 357 
 Moreover, the expression levels of MPO in neutrophils from AD were 358 
significantly lower compared to HD (P = .0002; Fig. 6D). MPO contributes to 359 
antimicrobial activity and NET formation.36 In line with this phenotypic change, 360 
neutrophils from AD showed significantly impaired NET formation (P < .0001, AD 361 
vs HD) compared to the ones isolated from HD upon stimulation with PMA (Fig. 6E). 362 
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 Overall, human neutrophils from AD resemble IL-4-/IL-13-stimulated 363 
neutrophils in terms of migratory phenotype and NET formation. 364 
 365 
Human neutrophils stimulated with serum from allergic individuals show 366 
similarity with IL-4/IL-13 stimulated cells 367 
To further evaluate whether soluble components of AD serum can affect neutrophils, 368 
we incubated freshly-isolated neutrophils from HD with serum from HD or AD. 369 
Compared to incubation with HD serum, AD serum severely affected the ability of 370 
HD neutrophils to form NETs, as measured by counting (P < .0001) and assessment 371 
of DNA area (P = .0056; Fig. 7A). Moreover, the migration of HD neutrophils toward 372 
100 ng/mL CXCL8 was significantly reduced upon incubation with AD serum (P < 373 
.0001), and concomitant use of an anti-CD124 monoclonal antibody was able to 374 
partially restore their migration (P = .0033, HD neutrophils preincubated with anti-375 
CD124 vs Ctrl followed by AD serum; Fig. 7B), indicating that IL-4 and/or IL-13 in 376 
AD serum significantly affected the HD neutrophils. These functional changes in HD 377 
neutrophils incubated with AD serum were accompanied by a significant decrease of 378 
CXCR1 (P < .0001) and CXCR2 (P = .0004), whereas CXCR4 remained unchanged 379 
(Fig. E4). 380 
 Overall, serum from allergic individuals alters the neutrophil chemotaxis and 381 




Our data demonstrate that the prototypic type 2 cytokines IL-4 and IL-13 adversely 385 
affect several functional properties of human neutrophils. As a result, neutrophils 386 
appear desensitized toward CXCL8-mediated chemotaxis in vitro and in vivo as well 387 
as to stimulation-induced NET formation. Such IL-4R-mediated conditioning of 388 
neutrophils results in a phenotype characterized by low CXCR1 and CXCR2 and 389 
decreased MPO expression. These phenotypic and functional characteristics are also 390 
observed in freshly-isolated neutrophils from allergic subjects as well as upon 391 
incubation of HD neutrophils with AD serum. 392 
 Our data suggest that human neutrophils stimulated by their IL-4Rs enter an 393 
activation or differentiation state that differs from neutrophils freshly isolated from 394 
peripheral blood of healthy individuals. The question arises whether IL-4/IL-13-395 
conditioned neutrophils represent senescent, aged, exhausted or apoptosis-prone cells. 396 
We have not observed increased apoptosis of IL-4/IL-13-conditioned neutrophils. 397 
Also, unlike senescent or aged neutrophils, showing decreased CD16 and increased 398 
CXCR4 and NET formation,1,37 CXCR4 expression remained unchanged in IL-4/IL-399 
13-conditioned neutrophils, although CD16 was slightly decreased, and they showed a 400 
deficiency in NET formation, which is contrary to what was observed for senescent 401 
and aged neutrophils. 402 
 In terms of NET formation, IL-4/IL-13-conditioned neutrophils could present 403 
with a delayed type of NET formation or, alternatively, IL-4R signaling could skew 404 
neutrophils toward suicidal vs. vital NET formation.38-40 Although we did not observe 405 
a kinetic delay in NET formation or increased apoptosis in IL-4/IL-13-conditioned 406 
neutrophils, we cannot formally exclude these possibilities. We prefer to consider IL-407 
4/IL-13-conditioned neutrophils as "alternatively-activated" neutrophils, similar to 408 
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their IL-4/IL-13-conditioned counterparts in macrophages.12 "N2" neutrophils have 409 
been described in the context of tumor-infiltrating pro-tumorigenic neutrophils.41 410 
Whether IL-4/IL-13-conditioned neutrophils resemble N2 neutrophils is an interesting 411 
question for future studies. 412 
 Steady-state and induced levels of IL-4Rs on neutrophils will determine their 413 
susceptibility to IL-4 and IL-13. We found that freshly-isolated human neutrophils 414 
from whole blood expressed significant levels of type 1 and type 2 IL-4Rs. This 415 
finding slightly contrasts with a previous publication describing only the presence of 416 
type 1 IL-4Rs on human neutrophils.35 Yet, another publication reported the absence 417 
of type 1 IL-4Rs but the expression of type 2 IL-4Rs on mouse neutrophils.28 These 418 
differences might indicate discrepancies between human and mouse neutrophils, and 419 
they might result from different neutrophil preparation methods, such as the 420 
preincubation of neutrophils with autologous serum to prevent nonspecific binding via 421 
Fc receptors.35 Importantly, IL-4R expression on human neutrophils was further 422 
increased by certain stimuli, most notably G-CSF. This result is consistent with what 423 
has been reported in mice.28 Also, Toll-like receptor (TLR) ligands and common 424 
vaccine adjuvants, including LPS, alum and incomplete Freund's adjuvant, have been 425 
shown in mice to upregulate CD124 on CD11b+ myeloid cells, which include 426 
monocytes and neutrophils.42 G-CSF and TLR ligands are typically released upon 427 
inflammation and infection, indicating that such conditions increase the neutrophils' 428 
sensitivity to IL-4 and IL-13. 429 
 IL-4/IL-13-mediated conditioning of neutrophils, as described here, could play 430 
a role in shaping the different asthma phenotypes, including eosinophilic and 431 
neutrophilic asthma.17,43,44 Thus, production of IL-4 and/or IL-13 and the ensuing IL-432 
4R engagement could contribute to the eosinophilic variant of asthma by inhibiting 433 
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the recruitment of neutrophils into the tissues. This suggestion is in line with mouse 434 
data showing that eosinophilic asthma is dependent on IL-4, IL-13, and STAT6, 435 
whereas lack of these factors favors neutrophilic asthma in mice.27 Also, this 436 
hypothesis fits with publications reporting that type 2 and type 3 immune signatures 437 
are mutually exclusive in asthma patients.17 Conversely, it is known that rhinovirus 438 
infection can result in neutrophil activation and release of NETs along with disease 439 
exacerbation in asthmatic subjects.6,22 Moreover, certain IL4Ra genotypes predispose 440 
to a mixed eosinophilic-neutrophilic asthma presentation.23-26 These considerations 441 
suggest that IL-4R-mediated conditioning of neutrophils can be overwritten by 442 
stronger stimuli, such as an infection, or by interference with normal IL-4R signaling. 443 
 For eosinophilic asthma, IL-4R-interfering biologic agents should not only 444 
dampen type 2 inflammation and improve disease45,46 but also re-invigorate 445 
neutrophils thereby strengthening anti-pathogen immunity. This has so far not been 446 
investigated. Contrarily, the use of IL-4R-stimulating molecules could be used in 447 
diseases with predominant neutrophilic inflammation, an idea that has been tested in 448 
both humans and mice. In psoriasis, a skin and joint disease characterized by 449 
prominent neutrophil infiltration, a small proof-of-concept clinical trial showed that 450 
administration of recombinant IL-4 improved skin disease, which the authors 451 
interpreted as a skewing from Th1 to Th2 cell responses.47 In mice and rats, provision 452 
of recombinant IL-4 improved experimental arthritis,48,49 which in the collagen-453 
induced DBA/1 mouse model is known to rely on IL-1b and G-CSF-dependent 454 
neutrophil activity.50,51 However, translation and use of recombinant IL-4 in humans 455 
is currently hampered by the very short in vivo half-life and dose-dependent toxic 456 
adverse effects of IL-4, which might be improved by provision of long-acting IL-4 457 
formulations.52 458 
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 Collectively, our data demonstrate that IL-4R engagement in human 459 
neutrophils antagonizes several effector functions, which might open possibilities to 460 
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Figure legends 645 
Figure 1. Human neutrophils express functional type 1 and type 2 IL-4 646 
receptors. A, Schematic representation of the type 1 and type 2 IL-4R. B to D, 647 
Expression of IL-4R subunits on human neutrophils of healthy donors (HD). 648 
Representative histograms of CD124 (B), CD132 (C), and CD213a1 (D) after 649 
isolation (T0; black lines) or following stimulation for 24 h with granulocyte colony-650 
stimulating factor (G-CSF; blue lines). Fluorescence minus one (FMO) values are 651 
represented by histograms filled with grey color. Bars represent the geometric mean 652 
fluorescence intensity (GMFI) of the indicated receptor subunits at T0 (grey bars) or 653 
upon 24 h stimulation with G-CSF (blue bars). Data are presented as mean ± standard 654 
deviation (SD) of n = 15 donors. Significance of the differences between groups was 655 
calculated using Student's t-test. (E) STAT pathways activated by G-CSF, IL-4, or IL-656 
13. Phosphorylated STAT3 (pSTAT3; top row), pSTAT5 (middle row), and pSTAT6 657 
(bottom row) in human neutrophils upon stimulation for the indicated times with G-658 
CSF (left column), IL-4 (middle column) or IL-13 (right column). Diagrams represent 659 
MFI of pSTATs at indicated time points. Small squares show representative flow 660 
cytometry histograms of pSTATs at 0 and 5 min. Data are shown as mean ± SD and 661 
are representative of n = 10 independent experiments using unrelated donors. 662 
Statistical significance was calculated using Friedman test with Dunn’s multiple 663 
comparisons test; ns, Not significant. 664 
665 
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Figure 2. Inhibition of NET formation by IL-4 or IL-13 stimulation in vitro. A, 666 
Freshly-isolated HD blood neutrophils were directly assessed (Ctrl) or stimulated for 667 
2 h with 100 nM phorbol 12-myristate 13-acetate (PMA) in medium alone (Medium; 668 
RPMI 1640 with 1% of FBS) or medium plus granulocyte colony-stimulating factor 669 
(G-CSF; 150 ng/mL), IL-4 (150 ng/mL) or IL-13 (150 ng/mL). Neutrophils were 670 
stained with DAPI and analyzed by confocal microscopy at 40-fold (40x) and 80-fold 671 
(80x) magnification. Experiments were repeated using n = 10 unrelated donors. Scale 672 
bar 100 µm. B, Bar histograms represent NET+ neutrophils treated as in A, including 673 
direct assessment (Ctrl) or upon 2 h PMA stimulation with medium alone (Medium; 674 
black filled bar), medium containing G-CSF (150 ng/mL; blue open bar), medium 675 
containing IL-4 (150 ng/mL; red filled bar), or medium containing IL-13 (150 ng/mL; 676 
blue filled bar). Neutrophils were stained with DAPI and analyzed by confocal 677 
microscopy, followed by manual counting of NET+ neutrophils (left panel) or 678 
automatic quantification of the DNA area (µm2) using the DANA plug-in for ImageJ 679 
(right panel). Data are shown as mean ± SD of at least n = 10 independent 680 
experiments with unrelated donors. Significance of the differences between groups 681 
was calculated using one-way ANOVA; ns, Not significant. 682 
683 
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Figure 3. Human neutrophil chemotaxis is inhibited by IL-4 and IL-13. A to D, 684 
Migration of freshly-isolated HD neutrophils toward a set concentration of CXCL8 685 
(100 ng/mL) at different time points (A and C) or following stimulation for 60 min 686 
and 120 min (left and right panels, respectively, B and D) with medium (black), 687 
medium plus IL-4 (150 ng/mL; red; A and B), or medium plus IL-13 (150 ng/mL; 688 
blue; C and D). E and F, Chemotaxis of freshly-isolated HD neutrophils toward 689 
titrated concentrations of CXCL8 following stimulation for 2 h with set 690 
concentrations of IL-4 (150 ng/mL, red; E) or IL-13 (150 ng/mL, blue; F). G and H, 691 
Migration of freshly-isolated HD neutrophils toward a set concentration of CXCL8 692 
(100 ng/mL) after 2 h of stimulation with titrated concentrations of IL-4 (red filled 693 
bars; G) or IL-13 (blue filled bars; H). Shown are counts (A, C, E, and F) or 694 
percentages (B, D, G, and H) of migrated neutrophils. Data are presented as mean ± 695 
SD of three independent experiments with n = 10-12 unrelated donors. Significances 696 
between the groups were calculated by one-way ANOVA (A, C, and E to H) or 697 




Figure 4. Migration of human neutrophils in vivo. A, Experimental setup of the 701 
airpouch in NOD-scid-Il2rg–/– (NSG) mouse model. B, Representative flow cytometry 702 
analysis of human (h) CD45+ mouse (m) CD45– cells (left panel) and hCD16+ 703 
hCD66b+ neutrophils (right panel) in the airpouch. C, Bars represent the counts of 704 
human neutrophils, on the total of CD45+ human cells,  preconditioned for 2 h with 705 
medium (RPMI 1640 containing 1% of FBS, black bars; n = 8) or with IL-4 (150 706 
ng/mL, red filled bars; n = 10) in the airpouch (left panel) or spleen (right panel). D, 707 
Counts of human neutrophils preconditioned for 6 h with G-CSF (150 ng/mL, blue 708 
empty bars; n = 6) or with IL-4 (red filled bars; n = 6) collected from the airpouch 709 
(left panel) or spleen (right panel). Data are presented as mean ± SD of five (C) or 710 
three (D) independent experiments using unrelated HD. Significance of the 711 
differences between groups was calculated using Student's t-test; ns, Not significant.  712 
713 
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Figure 5. Modulation of CXC chemokine receptors CXCR1 and CXCR2 on 714 
human neutrophils. A, Expression of CXC chemokine receptors CXCR1, CXCR2, 715 
and CXCR4 on HD neutrophils following stimulation for 6 h with medium (RPMI 716 
1640 containing 1% of FBS, black filled bars), IL-4 (red filled bars), or IL-13 (blue 717 
filled bars). Shown are the GMFI of indicated CXC chemokine receptors. Data are 718 
shown as mean ± SD of n = 10 donors. Significance of the differences between groups 719 
was calculated using one-way ANOVA. B, Representative flow cytometry analysis of 720 
annexin V and propidium iodide (PI) staining on HD neutrophils treated as in A. 721 
Numbers in plot indicate the percentage. Experiments were repeated n = 10 times with 722 




Figure 6. Human neutrophils from healthy versus allergic individuals. A to D, 726 
Freshly-isolated neutrophils from HD (black open bars) and allergic donors (AD; blue 727 
filled bars) were assessed for percentages and counts (A; HD n = 20, AD n = 24), 728 
CD16 GMFI (B; HD n = 42, AD n = 24), CXC chemokine receptors CXCR1, 729 
CXCR2, and CXCR4 GMFI values (C; HD n = 50, AD n = 20), and MPO GMFI (D; 730 
HD n = 29, AD n = 16). In A, bar histogram represents neutrophil percentages (left Y 731 
axis) and symbols the absolute neutrophil counts (right Y axis) in HD (black bar and 732 
circle) and AD (blue filled bar and square). Data in B to D are presented as GMFI 733 
mean ± SD of different and unrelated donors. E, NET formation in HD (n = 10) or 734 
AD (n = 11) neutrophils after stimulation with 100 nM of PMA for 2 h. Neutrophils 735 
were stained with DAPI and analyzed by confocal microscopy (left panel), followed 736 
by manual counting of NET+ neutrophils (middle panel) or automatic quantification 737 
of the DNA area (µm2) using the DANA plug-in for ImageJ (right panel). Scale bar is 738 
100 µm. Data are presented as mean ± SD of several donors. Significance of the 739 




Figure 7. Serum of allergic patients affects NET formation and migration of 743 
healthy human neutrophils. A, NET formation in HD neutrophils stimulated for 6 h 744 
with HD serum or AD serum, followed by stimulation with PMA (100 ng/mL) for 2 h 745 
and assessment. Neutrophils were stained and analyzed as described in Fig. 6E. Scale 746 
bar is 200 µm. Data are presented as mean ± SD of n = 10 unrelated donors. B, 747 
Chemotaxis of HD neutrophils toward a set concentration of CXCL8 (100 ng/mL) 748 
following stimulation for 2 h with HD serum (10% in RPMI 1640; grey bars) or AD 749 
serum (10% in RPMI 1640; red bars) together with an isotype-matched antibody 750 
(Ctrl; filled bars) or an anti-human CD124 antibody (5 µg/mL; Anti-CD124; striped 751 
bars). Shown are percentages of migrated neutrophils. Data are presented as mean ± 752 
SD of n = 10 unrelated donors. Significance of the difference between groups was 753 
calculated using Student's t-test (A) or one-way ANOVA (B); ns, Not significant. 754 
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